» Articles » PMID: 14595706

Langerhans Cell Histiocytosis Patients Have HLA Cw7 and DR4 Types Associated with Specific Clinical Presentations and No Increased Frequency in Polymorphisms of the Tumor Necrosis Factor Alpha Promoter

Overview
Specialties Oncology
Pediatrics
Date 2003 Nov 5
PMID 14595706
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Current theory on the etiology of Langerhans cell histiocytosis (LCH), formerly Histiocytosis-X, is that abnormality(ies) of the immune system are responsible for dysregulation of Langerhans cells (LC) in patients' lesions. Among the known abnormalities in LCH patients are increased amounts of tumor necrosis factor alpha (TNF-alpha) and other cytokines in the lesions.

Procedure: We investigated the human leukocyte antigen (HLA) phenotypes of 29 patients and 37 healthy family members to determine if any haplotypes segregate with the presence or locations of the disease. The lymphocyte subsets for 22 patients and 11 family members were also determined.

Results: Patients with single bone, multiple bone, or multi-system LCH had different relative proportions of HLA types. Patients presenting with single bone disease had an especially high frequency of the DR4 type. In this patient group, every Caucasian patient had either Cw7 or DR4. Lymphopenia was documented in patients who had been off therapy as well as those who only had surgical curetage of their lesions. Family members also had low numbers of T lymphocytes. There were fewer mutations of the TNF-alpha promoter in patients than in the general population.

Conclusions: Although there is an increased percentage of LCH patients with DR4 and/or Cw7 there was also an increased prevalence of this antigen as well as lymphopenia among unaffected family members. Additional genetic and/or environmental factors are necessary to explain this association. TNF-alpha promoter mutations are not responsible for the increased production of this cytokine.

Citing Articles

Apparent Lack of Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8 T Cells in Langerhans Cell Histiocytosis.

Kemps P, Zondag T, Steenwijk E, Andriessen Q, Borst J, Vloemans S Front Immunol. 2020; 10:3045.

PMID: 31998317 PMC: 6967030. DOI: 10.3389/fimmu.2019.03045.


Ultrasonographic features of Langerhans cell histiocytosis of the thyroid.

Chen E, Cheng P, Cai Y, Xiang Y, Zheng H, Xing H Int J Clin Exp Pathol. 2014; 7(3):1229-35.

PMID: 24696742 PMC: 3971333.


New insights into the molecular pathogenesis of langerhans cell histiocytosis.

Rizzo F, Cives M, Simone V, Silvestris F Oncologist. 2014; 19(2):151-63.

PMID: 24436311 PMC: 3926789. DOI: 10.1634/theoncologist.2013-0341.


Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.

Berres M, Allen C, Merad M Adv Immunol. 2013; 120:127-61.

PMID: 24070383 PMC: 3985340. DOI: 10.1016/B978-0-12-417028-5.00005-3.


Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells.

Allen C, Li L, Peters T, Leung H, Yu A, Man T J Immunol. 2010; 184(8):4557-67.

PMID: 20220088 PMC: 3142675. DOI: 10.4049/jimmunol.0902336.